Description
Anti-fibronectin extra domain-B Antibody, Non-Fucosylated (BioBet-235ZP) is a human monoclonal [(scFv - heavy - kappa) - IGHE - CH4]2 antibody against fibronectin extra domain-B. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Solid tumors
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced fibronectin extra domain-B antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FN1
Full Name
Fibronectin 1
Background
This gene encodes fibronectin, a glycoprotein present in a soluble dimeric form in plasma, and in a dimeric or multimeric form at the cell surface and in extracellular matrix. The encoded preproprotein is proteolytically processed to generate the mature protein. Fibronectin is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis. The gene has three regions subject to alternative splicing, with the potential to produce 20 different transcript variants, at least one of which encodes an isoform that undergoes proteolytic processing. The full-length nature of some variants has not been determined. [provided by RefSeq, Jan 2016]
Alternative Names
Radretumab;1253180-81-2;L19 I131 SIP;L19SIP;FN1;fibronectin 1;fibronectin;CIG;cold insoluble globulin;FINC;GFND2;LETS;migration stimulating factor;MSF;cold-insoluble globulin;migration-stimulating factor;FN;FNZ;ED-B;GFND;DKFZp686H0342;DKFZp686I1370;DKFZp6
Gene ID
2335
UniProt ID
P02751
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with FN1 include Spondylometaphyseal Dysplasia, Corner Fracture Type and Glomerulopathy With Fibronectin Deposits 2.
Related Pathways
Its related pathways are Association Between Physico-Chemical Features and Toxicity Associated Pathways and Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway.
Function
1.Fibronectin binds to the cell surface and various compounds, including collagen, fibrin, heparin, DNA, and actin. Fibronectin is involved in cell adhesion, cell movement, conditioning, wound healing and cell morphology maintenance. The matrix assembly process mediated by fibronectin fibroblasts participates in the compaction of osteoblasts, which is essential for osteoblast mineralization. Involved in the regulation of type I collagen deposition by osteoblasts 2.Anastellin binds to fibronectin and induces fiber formation. This fibronectin polymer, known as super fibronectin, exhibits enhanced adhesion properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.
Post-translational modifications
Sulfated. It is not known whether both or only one of Thr-2064 and Thr-2065 are/is glycosylated. Forms covalent cross-links mediated by a transglutaminase, such as F13A or TGM2, between a glutamine and the epsilon-amino group of a lysine residue, forming homopolymers and heteropolymers (e.g. fibrinogen-fibronectin, collagen-fibronectin heteropolymers). Phosphorylated by FAM20C in the extracellular medium. Proteolytic processing produces the C-terminal NC1 peptide, anastellin. Some lysine residues are oxidized to allysine by LOXL3, promoting fibronectin activation and matrix formation.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
[(scFv - heavy - kappa) - IGHE - CH4]2
Antibody Clone
BioBet-235ZP
Description
Recombinant monoclonal antibody to fibronectin extra domain-B. Radretumab is an antineoplastic. It binds to fibronectin extra domain-B.
Antibody Indication
Solid tumors
